What is a decentralized clinical trial? A decentralized clinical trial is a study that comes to the participant, not the other way around. People join from home, consent online, use the product as they normally would, and report how they feel through digital surveys and home kits. No clinic visits. No research site. No geographic filter on who can participate.

Traditional trials limit participation by geography, time, and access to clinical sites. Decentralized models remove those barriers by enabling remote recruitment, at-home product use, and digital data collection. Participants complete assessments and report outcomes through mobile platforms, wearables, or connected tools, on their schedule, in their environment.

That shift has real implications for who ends up in the data. Without geographic constraints, decentralized trials recruit broader, more diverse populations across geographies, demographics, and lifestyles. Because participants live their real lives during the trial, outcomes reflect how a product actually performs, not how it performs in a controlled environment built to make it look good. That is the definition of external validity in decentralized clinical trials for wellness brands. And for a consumer product used at home, that is the necessary insight.

Decentralized trials also generate continuous, longitudinal data. Instead of relying on infrequent clinic visits, Radicle's platform collects real-world data from wellness participants weekly across the full trial period through automated surveys, nudge reminders, and direct participant communication, giving a complete view of how outcomes evolve over time.

The historical objection to decentralized designs was rigor. Removing the clinic meant removing the controls. That is no longer the case. Radicle's Proof-as-a-Service model integrates randomization, placebo control, and powered endpoints directly into the decentralized framework, so scale and rigor are not a tradeoff. The Food and Drug Administration (FDA) finalized guidance on decentralized clinical trials in September 2024. The methodology is regulator-endorsed, with published best practices. What Radicle has done is apply that same standard to decentralized clinical trials for wellness products, where rigorous evidence has historically been rare.

From a strategic standpoint, this makes decentralized trials repeatable evidence infrastructure, not a one-time credibility play. Brands can generate clinically robust data across real populations, produce claims language that meets the Federal Trade Commission’s (FTC) standards, and use subpopulation findings to identify exactly who the product works for. That is the foundation of lasting differentiation.

The tradeoff between rigor and scale is no longer real. Radicle runs gold-standard decentralized clinical trials for wellness brands in the real world and delivers evidence brands can actually use.

Decentralized trials reach the real world. Participants join from home, use the product as they normally would, and report outcomes digitally. No clinic visits. No geographic filter.

Diverse populations produce more useful data. Without site-based constraints, decentralized clinical trials for wellness brands recruit across geographies, demographics, and lifestyles, so results reflect who actually buys the product.

Longitudinal data tells the complete story. Weekly digital data collection across the full trial period captures how outcomes evolve, not just a snapshot at the end.

Rigor and scale are not a tradeoff. Radicle's Proof-as-a-Service model integrates randomization, placebo control, and powered endpoints into every decentralized design. The FDA finalized guidance on this methodology in September 2024.

Evidence becomes a strategic asset. FTC-defensible claims, subpopulation insights, and a repeatable evidence infrastructure built on real-world data from real populations.

A decentralized clinical trial is a study where participants join remotely from home rather than visiting a clinical site. They consent online, use the product as they normally would in daily life, and report outcomes through digital surveys, wearables, or connected tools. No clinic visits are required, which removes geographic and access barriers and allows brands to recruit broader, more diverse populations.

Traditional clinical trials require participants to travel to a physical research site, which limits who can participate by geography, time, and access. Decentralized clinical trials conduct the same rigorous research remotely, using digital data collection instead of clinic-based measurement. The result is a more diverse study population and outcomes that reflect how a product performs in real life, not in a controlled environment built to make it look good.

Yes. Decentralized clinical trials for wellness can include the same rigorous design elements as traditional trials, including randomization, blinding, placebo control, and powered endpoints. The FDA finalized guidance on decentralized clinical trial methodology in September 2024, endorsing the approach with published best practices. Radicle's Proof-as-a-Service model applies that same standard to consumer wellness products.

The FDA finalized guidance on decentralized clinical trials for drug development trials in September 2024. The guidance endorses decentralized methods as a legitimate and rigorous approach to clinical research, with published best practices covering remote consent, digital data collection, and product use outside clinical sites. This makes decentralized clinical trial methodology regulator-endorsed, not experimental.

Decentralized clinical trials for wellness brands produce evidence that is both scientifically rigorous and commercially applicable. Because participants use the product in their real lives, outcomes reflect real-world performance rather than performance in a controlled setting. Brands get FTC-defensible claim language, subpopulation insights about who the product works for, and a repeatable evidence infrastructure that builds lasting brand differentiation.